Back to the search results

Charité - Universitätsmedizin Berlin

Charitéplatz 1
10117 Berlin

Phone: 030-45050
Fax: 030-450570-953
Mail: ed.etirahc@ofni

  • Number of beds: 3.011
  • Number of specialist departments: 69
  • Number of inpatient cases: 121.801
  • Number of partial inpatient cases: 8.803
  • Number of outpatient cases: 1.561.222
  • Number of cases of inpatient-equivalent psychiatric treatment (StäB): 2.249
  • Hospital owners: Land Berlin
  • Type of provider: öffentlich
  • University Hospital
  • Academic teaching hospital
External comparative quality assurance
Further information
  • External quality assurance according to state law
    No participation
Quantity performed 364
Exception? No exception
Quantity performed 38
Exception? No exception
Quantity performed 137
Exception? No exception
Quantity performed 56
Exception? No exception
Quantity performed 179
Exception? No exception
Quantity performed 363
Exception? No exception
Overall result forecast presentation: yes
Quantity performed reporting year: 364
Quantity forecast year: 352
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 38
Quantity forecast year: 44
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 137
Quantity forecast year: 142
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 56
Quantity forecast year: 60
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 179
Quantity forecast year: 200
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 363
Quantity forecast year: 380
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 101
Quantity forecast year: 102
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 384
Quantity forecast year: 436
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 96
Quantity forecast year: 107
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
No. Explanation
CQ01 Quality assurance measures for inpatient care with the indication abdominal aortic aneurysm
CQ08 Measures for quality assurance of cardiac surgery care in children and adolescents according to Article 136, para. 1, sentence 1, no. 2 of the SGB V
CQ05 Measures for quality assurance in the care of pre-term and full-term neonates – Perinatal Centre LEVEL 1
CQ02 Quality assurance measures for the inpatient care of children and adolescents with haemato-oncological diseases
CQ03 Quality assurance measures for the implementation of positron emission tomography (PET) in hospitals for the indications non-small-cell lung cancer (NSCLC) and solid pulmonary nodules
CQ24 Quality assurance measures for allogeneic stem cell transplantation for multiple myeloma (valid until 30 June 2022)
CQ25 Measures for quality assurance in the performance of minimally invasive heart valve interventions pursuant to Article 136, para. 1, sentence 1, number 2 for hospitals licensed in accordance with Article 108 of the SGB V
CQ26 Decision on measures for quality assurance of targeted lung denervation by catheter ablation in chronic obstructive pulmonary disease
CQ27 Guideline on quality assurance measures for inpatient care with bronchoscopic lung volume reduction procedures for severe emphysema (QS Guideline bronchoscopic LVR /QS-RL BLVR)
  • Clarifying chat completed: no
  • Clarifying chat not completed: no
  • No participation in clarifying chat: no
  • Notification of non-fulfilment of nursing care not made: yes
Number Group
1835 Medical specialists (m/f) , psychological psychotherapists (m/f) and child and adolescent psychotherapists (m/f) who are subject to the obligation to undergo further training*
231 Number of medical specialists (m/f) from no. 1 who have completed a five-year period of further training and are therefore subject to the obligation to provide evidence
193 Number of those persons from no. 2 who have provided proof of further training according to Article 3 of the G-BA regulations
* according to the “Provisions of the Joint Federal Committee for the Further Training of Medical Specialists (m/f), Psychological Psychotherapists (m/f) and Child and Adolescent Psychotherapists (m/f) in Hospitals”

According to Section 4 (2) of the Quality Management Guideline, facilities must provide for the prevention of and intervention in cases of violence and abuse as part of their internal quality management. The aim is to prevent, recognise and respond appropriately to abuse and violence, particularly against vulnerable patient groups such as children and adolescents or people in need of help, and also to prevent it within the facility. The respective procedure is aligned with the size of the facility, the range of services and the patients in order to define customised solutions for sensitising the teams as well as other suitable preventative and interventional measures. These may include information materials, contact addresses, training/education, codes of conduct, recommendations for action/intervention plans or comprehensive protection concepts.

  • Is a protection concept in place? Yes
Gemäß § 4 Absatz 2 in Verbindung mit Teil B Abschnitt I § 1 der Qualitätsmanagement-Richtlinie haben sich Einrichtungen, die Kinder und Jugendliche versorgen, gezielt mit der Prävention von und Intervention bei (sexueller) Gewalt und Missbrauch bei Kindern und Jugendlichen zu befassen (Risiko- und Gefährdungsanalyse) und – der Größe und Organisationsform der Einrichtung entsprechend – konkrete Schritte und Maßnahmen abzuleiten (Schutzkonzept). In diesem Abschnitt geben Krankenhäuser, die Kinder und Jugendliche versorgen, an, ob sie gemäß § 4 Absatz 2 in Verbindung mit Teil B Abschnitt I § 1 der Qualitätsmanagement-Richtlinie ein Schutzkonzept gegen (sexuelle) Gewalt bei Kindern und Jugendlichen aufweisen.
  • Drug commission

Zentrales QM Handbuch

31.12.2022

  • Bereitstellung einer geeigneten Infrastruktur zur Sicherstellung einer fehlerfreien Zubereitung
  • Zubereitung durch pharmazeutisches Personal
  • Anwendung von gebrauchsfertigen Arzneimitteln bzw. Zubereitungen
  • Vorhandensein von elektronischen Systemen zur Entscheidungsunterstützung (z.B. Meona®, Rpdoc®, AIDKlinik®, ID Medics® bzw. ID Diacos® Pharma)
  • Fallbesprechungen
  • Maßnahmen zur Vermeidung von Arzneimittelverwechslung
  • Spezielle AMTS-Visiten (z. B. pharmazeutische Visiten, antibiotic stewardship, Ernährung)
  • Teilnahme an einem einrichtungsübergreifenden Fehlermeldesystem (siehe Kapitel 12.2.3.2)
  • Aushändigung von arzneimittelbezogenen Informationen für die Weiterbehandlung und Anschlussversorgung der Patientin oder des Patienten im Rahmen eines (ggf. vorläufigen) Entlassbriefs
  • Aushändigung von Patienteninformationen zur Umsetzung von Therapieempfehlungen
  • Aushändigung des Medikationsplans
  • bei Bedarf Arzneimittel-Mitgabe oder Ausstellung von Entlassrezepten
The instruments and measures to promote drug therapy safety are presented with a focus on the typical procedures of the medication process in inpatient patient care. A special feature of the medication process in the inpatient environment is the transition management during admission and discharge. The instruments and measures listed below address structural elements, e.g. special IT equipment and work materials, as well as process aspects, such as work descriptions for particularly risky process steps or concepts for securing typical risk situations . In addition, proven measures to avoid or learn from medication errors can be specified. The hospital presents here which aspects it has already dealt with and which measures it has specifically implemented. The following aspects can be presented, if necessary using free text fields:
- Admission to hospital, including anamnesis
; Instruments and measures are presented for determining the old medication (drug history), the subsequent clinical assessment and the switch to the medication available in the hospital (house list), as well as for documenting both the patient's original medication and that for hospital treatment adapted medication.
- Medication process in the hospital
In this context, the following sub-processes are assumed as examples: drug history - prescription - patient information - drug delivery - drug use - documentation - therapy monitoring - result assessment. Instruments and measures for safe medication prescription can be presented, e.g. B. in terms of readability, clarity and completeness of the documentation, but also in terms of area of ​​application, effectiveness, benefit-risk ratio, tolerability (including potential contraindications, interactions, etc.) and resource considerations. Information can also be provided to support reliable medication ordering, delivery and use or administration.
- Discharge
In particular, the measures taken by hospitals can be presented to ensure that information on drug therapy is structured and passed on to doctors and physicians providing further treatment, as well as the appropriate provision of patients with drug information, medication plans and medications. Drug prescriptions are made.
AMTS is the totality of measures to ensure an optimal medication process with the aim of reducing medication errors and thus avoidable risks for patients during drug therapy. A prerequisite for the successful implementation of these measures is that AMTS is practised as an integral part of daily routine in an interdisciplinary and multi-professional approach.
Job
Explanation

als Universitätsmedizin hat die Charité eigene Professuren sowie Dozierende und Lehrbeauftragte

Explanation

die vollständige Studierendenausbildung in den grundständigen Studiengängen Medizin (als Modell), Zahnmedizin und Gesundheitswissenschaften (Bachelor)/Health Professions Education (Master), Public Health (Master), Pflegewissenschaft (Bachelor) und Angewandte Hebammenwissenschaft wird durchgeführt

Explanation

die Charité führt eine Vielzahl projektbezogener Kooperationen mit anderen Universitäten, Hochschulen und außeruniversitären Forschungseinrichtungen durch

Explanation

die Charité führt eine Vielzahl entsprechender Studien durch

Explanation

die Charité führt eine Vielzahl entsprechender Studien durch

Explanation

die Charité führt eine Vielzahl selbst von Wissenschaftler:innen der Charité eigeninitiierter Studien durch, dazu existieren u.a. zentrale Unterstützungsstrukturen, wie das Clinical Trial Office (CTO) und die QA-Unit Klinische Studien

Explanation

Wissenschaftler/innen der Charité sind an einer Vielzahl wissenschaftlicher Journale in den Editorial Boards beteiligt. Wichtige Lehrbücher der Biomedizin beinhalten umfassende Beiträge aus der Charité

Explanation

die Charité hat als universitäre Einrichtung das Promotionsrecht und vergibt den Dr. med, den Dr. med. dent, den Dr. rer. medic. sowie einen PhD

Training in other healing professions
Comment

Comment

Comment

Comment

Comment

Comment

Die Hebammenausbildung ist seit dem WS 2021/2022 akademisiert und läuft als Ausbildung in Heilberufen aus.

Comment

Herr Ernst-Christoph Bösener

Patientenfürsprecher CBF - somatische Bereiche

Charitéplatz 1
10117 Berlin

Phone: 030 -450577-329
Mail: ed.nilreB@SFBC.etirahC-FtaP

Frau Gülgün Sahin

Patientenfürsprecherin CVK

Charitéplatz 1
10117 Berlin

Phone: 030 -450577-248
Mail: ed.nilreB@KVC.etirahC-FtaP

Frau Antonia Schwarz

Patientenfürsprecherin CBF - Psychiatrie

Charitéplatz 1
10117 Berlin

Phone: 030 -450-50
Mail: ed.nilreB@SFBC.etirahC-FtaP

Frau Britta Hoffmann

Patientenfürsprecherin CCM-somatische Bereiche

Charitéplatz 1
10117 Berlin

Phone: 030 -450570-170
Mail: ed.nilreB@mos.etirahC-FtaP

Frau Marion Morres

Patientenfürsprecherin CCM-Psychiatrie

Charitéplatz 1
10117 Berlin

Phone: 030 -450570-134
Mail: ed.nilreB@ysp.etirahC-FtaP

Frau Ewa Kopitzki

Zentrales Beschwerdemanagement Klinikumsleitung

Charitéplatz 1
10117 Berlin

Phone: 030 -450577-008
Mail: ed.etirahc@nedrewhcsebdnubol

Frau Tosca Hrnjak

Zentrales Beschwerdemanagement Vorstand Krankenversorgung

Charitéplatz 1
10117 Berlin

Phone: 030 -450577-319
Mail: ed.etirahc@nedrewhcsebdnubol

Frau Meray Ben Chobba

Zentrales Beschwerdemanagement Vorstand Krankenversorgung

Charitéplatz 1
10117 Berlin

Phone: 030 -450577-069
Mail: ed.etirahc@nedrewhcsebdnubol

Zentrales Beschwerdemanagement Vorstand Krankenversorgung Zentrales Beschwerdemanagement Vorstand Krankenversorgung

Zentrales Beschwerdemanagement Vorstand Krankenversorgung

Charitéplatz 1
10117 Berlin

Phone: 030 -450577-318
Mail: ed.etirahc@nedrewhcsebdnubol

Dr. Nils Löber

Leiter Klinisches Qualitäts-und Risikomanagement

Charitéplatz 1
10117 Berlin

Phone: 030 -450577-046
Mail: ed.etirahc@rebeol.slin

Dr. Sibylle Semmler

Leitung Klinisches Qualitäts-und Risikomanagement

Charitéplatz 1
10117 Berlin

Phone: 030 -450-50
Mail: ed.etirahc@relmmes.ellybis

Prof. Dr. med. Ulrich Frei

Ärztlicher Direktor

Charitéplatz 1
10117 Berlin

Phone: 030 -450570-151
Mail: ed.etirahc@ierf.hcirlu

Prof. Dr. med. Martin Kreis

Ärztlicher Direktor

Charitéplatz 1
10117 Berlin

Phone: 030 -450570-151
Mail: ed.etirahc@sierk.nitram

Prof. Dr. med. Andreas Ströhle

Vorsitzender AMK

Charitéplatz 1
10117 Berlin

Phone: 030 -450561-102
Mail: ed.etirahc@ekehtopa

Frau Dr. med. Sybille Semmler

Leitung KQRM

Charitéplatz 1
10117 Berlin

Phone: 030 -450514-041
Mail: ed.etirahc@relmmes.ellibys

Frau Cindy Stoklossa

Leitung Sozialdienst

Charitéplatz 1
10117 Berlin

Phone: 004930 -4500571-071
Mail: ed.etirahc@assolkots.ydnic

Charitéplatz 1
10117 Berlin

Phone: 030-45050
Fax: 030-450570-953
Mail: ed.etirahc@ofni

Frau Judith Heepe

Pflegedirektorin

Charitéplatz 1
10117 Berlin

Phone: 030 -450577-021
Mail: ed.etirahc@epeeh.htiduj

Herr Nagi Salaz

Pflegedirektor (kommissarisch)

Charitéplatz 1
10117 Berlin

Phone: 030 -450577-021
Mail: ed.etirahc@zalas.igan

Frau Astrid Lurati

Direktorin des Klinikums

Charitéplatz 1
10117 Berlin

Phone: 030 -450570-051
Mail: ed.etirahc@itarul.dirtsa

Prof. Dr. Ulrich Frei

Ärztlicher Direktor

Charitéplatz 1
10117 Berlin

Phone: 030 -450570-151
Mail: ed.etirahc@ierf.hcirlu

Prof. Dr. Ulrich Frei

Ärztlicher Direktor

Charitéplatz 1
10117 Berlin

Phone: 030 -450570-151
Mail: ed.etirahc@ierf.hcirlu

Prof. Dr. Martin Kreis

Vorstand Krankenversorgung

Charitéplatz 1
10117 Berlin

Phone: 030 -450570-151
Mail: ed.etirahc@sierk.nitram

IK: 261101015

More IK: 261101015

Location number: 772563000

Old location number: 772563000